PT  - JOURNAL ARTICLE
AU  - Boltz, Kathy
ED  - Reck, Martin
TI  - ASSESS
DP  - 2015 Jun 19
TA  - MD Conference Express
PG  - 7--8
VI  - 15
IP  - 8
4099  - http://mdc.sagepub.com/content/15/8/7.short
4100  - http://mdc.sagepub.com/content/15/8/7.full
AB  - EGFR mutations can be analyzed with circulating tumor DNA, with an overall concordance of EGFR mutation status of 89%. The low positive predictive value of 78% was likely due to false-negative tumor samples using less sensitive methodologies such as DNA sequencing or pyrosequencing, and it increased to 93% when highly sensitive methods such as the QIAGEN Therascreen RGQ PCR kit was used for both tissue/cytology samples and plasma samples.